Sup Figure 4 from Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers

Authors :: Anthony W. Tolcher
Johann S. de Bono
Daniel M. Sullivan
Michelle D. Garrett
Martin O. Leach
Nandita M. deSouza
Karen Swales
Simon P. Heaton
Shaun Decordova
Ruth Riisnaes
Lisa Lupinacci
Robert A. Beckman
Ernestina Tetteh
Liliana Delgado
Richard Baird
David Olmos
Kyriakos P. Papadopoulos
Ivy Fearen
Andrea Biondo
Nina Tunariu
Amita Patnaik
Li Yan
Timothy A. Yap
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Sup Figure 4. A 42-year-old female with metastatic breast cancer treated with 60mg QOD of MK-2206.

Tools